Journal article 12 views
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Deborah B Horn,
Donna H Ryan,
Sanja Giljanovic Kis,
Breno Alves,
Yiming Mu,
Sin Gon Kim,
Jens Aberle,
Steve Bain 
,
Sheryl Allen,
Elizabeth Sarker,
Qiwei Wu,
Adam Stefanski,
Irina Jouravskaya
,
Sheryl Allen,
Elizabeth Sarker,
Qiwei Wu,
Adam Stefanski,
Irina Jouravskaya
The Lancet, Volume: 406, Issue: 10522, Pages: 2927 - 2944
Swansea University Author:
Steve Bain
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1016/s0140-6736(25)02165-8
Abstract
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
| Published in: | The Lancet |
|---|---|
| ISSN: | 0140-6736 1474-547X |
| Published: |
Elsevier BV
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa71022 |
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|---|
| Funders: |
This study was funded by Eli Lilly and Company. |
| Issue: |
10522 |
| Start Page: |
2927 |
| End Page: |
2944 |